COVID-19 severe or critically | |
COVID-19 prophylaxis (excluding children) | |
neutralizing antibody | |
bamlanivimab monotherapy | BLAZE-2 US ... |
casirivimab/imdevimab (Ronapreve) | Cov-2069 ... |
cilgavimab and tixagevimab (Evusheld) | PROVENT |
9866 | Jurdi, 2022 | 1 | 11 | 0 | not a RCT | risk of bias not avaialble |